Titre : Calbindine-2

Calbindine-2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cognitive Dysfunction
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Calbindine-2 : Questions médicales les plus fréquentes", "headline": "Calbindine-2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Calbindine-2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-21", "dateModified": "2025-03-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Calbindine-2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Calbindines", "url": "https://questionsmedicales.fr/mesh/D064026", "about": { "@type": "MedicalCondition", "name": "Calbindines", "code": { "@type": "MedicalCode", "code": "D064026", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.157.125.090" } } }, "about": { "@type": "MedicalCondition", "name": "Calbindine-2", "alternateName": "Calbindin 2", "code": { "@type": "MedicalCode", "code": "D064032", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Eui-Man Jung", "url": "https://questionsmedicales.fr/author/Eui-Man%20Jung", "affiliation": { "@type": "Organization", "name": "Laboratory of Veterinary Biochemistry and Molecular Biology, Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea." } }, { "@type": "Person", "name": "Yeong-Min Yoo", "url": "https://questionsmedicales.fr/author/Yeong-Min%20Yoo", "affiliation": { "@type": "Organization", "name": "Laboratory of Veterinary Biochemistry and Molecular Biology, Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea." } }, { "@type": "Person", "name": "Eui-Bae Jeung", "url": "https://questionsmedicales.fr/author/Eui-Bae%20Jeung", "affiliation": { "@type": "Organization", "name": "Laboratory of Veterinary Biochemistry and Molecular Biology, Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea, ebjeung@chungbuk.ac.kr." } }, { "@type": "Person", "name": "Seon Young Park", "url": "https://questionsmedicales.fr/author/Seon%20Young%20Park", "affiliation": { "@type": "Organization", "name": "Laboratory of Veterinary Biochemistry and Molecular Biology, Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea." } }, { "@type": "Person", "name": "Changhwan Ahn", "url": "https://questionsmedicales.fr/author/Changhwan%20Ahn", "affiliation": { "@type": "Organization", "name": "Laboratory of Veterinary Biochemistry and Molecular Biology, Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.", "datePublished": "2022-10-17", "url": "https://questionsmedicales.fr/article/36251860", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/13506129.2022.2131384" } }, { "@type": "ScholarlyArticle", "name": "Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.", "datePublished": "2024-09-13", "url": "https://questionsmedicales.fr/article/39346594", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2024.1385089" } }, { "@type": "ScholarlyArticle", "name": "Reward network dysfunction is associated with cognitive impairment after stroke.", "datePublished": "2023-05-31", "url": "https://questionsmedicales.fr/article/37307650", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nicl.2023.103446" } }, { "@type": "ScholarlyArticle", "name": "Predictors of cognitive dysfunction one-year post COVID-19.", "datePublished": "2023-01-05", "url": "https://questionsmedicales.fr/article/36603126", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1037/neu0000876" } }, { "@type": "ScholarlyArticle", "name": "Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.", "datePublished": "2022-12-07", "url": "https://questionsmedicales.fr/article/36729842", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/RHU.0000000000001888" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines de transport", "item": "https://questionsmedicales.fr/mesh/D002352" }, { "@type": "ListItem", "position": 5, "name": "Protéines de liaison au calcium", "item": "https://questionsmedicales.fr/mesh/D002135" }, { "@type": "ListItem", "position": 6, "name": "Calbindines", "item": "https://questionsmedicales.fr/mesh/D064026" }, { "@type": "ListItem", "position": 7, "name": "Calbindine-2", "item": "https://questionsmedicales.fr/mesh/D064032" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Calbindine-2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Calbindine-2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Calbindine-2", "description": "Comment diagnostiquer une carence en calbindine-2 ?\nQuels examens sont utilisés pour évaluer la calbindine-2 ?\nLa calbindine-2 est-elle mesurable dans le sang ?\nQuels symptômes peuvent indiquer un problème avec la calbindine-2 ?\nY a-t-il des marqueurs spécifiques pour la calbindine-2 ?", "url": "https://questionsmedicales.fr/mesh/D064032?mesh_terms=Cognitive+Dysfunction&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Calbindine-2", "description": "Quels sont les symptômes d'une déficience en calbindine-2 ?\nLa calbindine-2 affecte-t-elle le système nerveux ?\nDes douleurs musculaires peuvent-elles être liées à la calbindine-2 ?\nLa fatigue est-elle un symptôme associé à la calbindine-2 ?\nPeut-on observer des troubles cognitifs liés à la calbindine-2 ?", "url": "https://questionsmedicales.fr/mesh/D064032?mesh_terms=Cognitive+Dysfunction&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Calbindine-2", "description": "Comment prévenir une carence en calbindine-2 ?\nLes suppléments de calcium sont-ils nécessaires ?\nY a-t-il des groupes à risque pour la calbindine-2 ?\nL'exposition au soleil est-elle importante ?\nDes tests réguliers sont-ils conseillés ?", "url": "https://questionsmedicales.fr/mesh/D064032?mesh_terms=Cognitive+Dysfunction&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Calbindine-2", "description": "Comment traiter une carence en calbindine-2 ?\nY a-t-il des médicaments pour réguler la calbindine-2 ?\nLa physiothérapie aide-t-elle en cas de dysfonction de la calbindine-2 ?\nDes changements alimentaires peuvent-ils aider ?\nLes exercices physiques sont-ils bénéfiques ?", "url": "https://questionsmedicales.fr/mesh/D064032?mesh_terms=Cognitive+Dysfunction&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Calbindine-2", "description": "Quelles complications peuvent survenir avec une carence en calbindine-2 ?\nLa calbindine-2 est-elle liée à des maladies chroniques ?\nDes troubles de l'humeur peuvent-ils être liés à la calbindine-2 ?\nLa calbindine-2 influence-t-elle le développement cognitif ?\nY a-t-il un risque accru de chutes ?", "url": "https://questionsmedicales.fr/mesh/D064032?mesh_terms=Cognitive+Dysfunction&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Calbindine-2", "description": "Quels facteurs augmentent le risque de carence en calbindine-2 ?\nLes troubles métaboliques sont-ils un facteur de risque ?\nLe mode de vie sédentaire influence-t-il la calbindine-2 ?\nLes régimes restrictifs sont-ils risqués ?\nLes antécédents familiaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D064032?mesh_terms=Cognitive+Dysfunction&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une carence en calbindine-2 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies musculaires peuvent aider à évaluer les niveaux de calbindine-2." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer la calbindine-2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'électrophorèse des protéines et l'immunohistochimie sont couramment utilisés." } }, { "@type": "Question", "name": "La calbindine-2 est-elle mesurable dans le sang ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, la calbindine-2 est principalement présente dans les tissus, pas dans le sang." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec la calbindine-2 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques ou musculaires peuvent suggérer un dysfonctionnement de la calbindine-2." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour la calbindine-2 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme la calmoduline peuvent être évalués en relation avec la calbindine-2." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en calbindine-2 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des spasmes musculaires, des tremblements et des troubles de la coordination." } }, { "@type": "Question", "name": "La calbindine-2 affecte-t-elle le système nerveux ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle crucial dans la transmission synaptique et la plasticité neuronale." } }, { "@type": "Question", "name": "Des douleurs musculaires peuvent-elles être liées à la calbindine-2 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une dysfonction de la calbindine-2 peut entraîner des douleurs musculaires et des crampes." } }, { "@type": "Question", "name": "La fatigue est-elle un symptôme associé à la calbindine-2 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une fatigue excessive peut résulter d'une mauvaise régulation du calcium par la calbindine-2." } }, { "@type": "Question", "name": "Peut-on observer des troubles cognitifs liés à la calbindine-2 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles cognitifs peuvent survenir en raison de l'implication de la calbindine-2 dans le cerveau." } }, { "@type": "Question", "name": "Comment prévenir une carence en calbindine-2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et des contrôles réguliers de la santé peuvent aider." } }, { "@type": "Question", "name": "Les suppléments de calcium sont-ils nécessaires ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être recommandés, surtout pour les personnes à risque de carence." } }, { "@type": "Question", "name": "Y a-t-il des groupes à risque pour la calbindine-2 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées et celles avec des troubles métaboliques sont plus à risque." } }, { "@type": "Question", "name": "L'exposition au soleil est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition au soleil aide à la synthèse de la vitamine D, essentielle pour la calbindine-2." } }, { "@type": "Question", "name": "Des tests réguliers sont-ils conseillés ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests réguliers peuvent aider à détecter précocement des anomalies." } }, { "@type": "Question", "name": "Comment traiter une carence en calbindine-2 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des suppléments de calcium et des thérapies ciblées." } }, { "@type": "Question", "name": "Y a-t-il des médicaments pour réguler la calbindine-2 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de médicaments spécifiques pour la calbindine-2." } }, { "@type": "Question", "name": "La physiothérapie aide-t-elle en cas de dysfonction de la calbindine-2 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la physiothérapie peut améliorer la force musculaire et la coordination." } }, { "@type": "Question", "name": "Des changements alimentaires peuvent-ils aider ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en calcium et en vitamine D peut soutenir la fonction de la calbindine-2." } }, { "@type": "Question", "name": "Les exercices physiques sont-ils bénéfiques ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des exercices réguliers peuvent améliorer la santé musculaire et nerveuse." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une carence en calbindine-2 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques et musculaires graves peuvent se développer." } }, { "@type": "Question", "name": "La calbindine-2 est-elle liée à des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme l'ostéoporose peuvent être exacerbées par une carence en calbindine-2." } }, { "@type": "Question", "name": "Des troubles de l'humeur peuvent-ils être liés à la calbindine-2 ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres de calcium peuvent affecter l'humeur et le comportement." } }, { "@type": "Question", "name": "La calbindine-2 influence-t-elle le développement cognitif ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une déficience peut nuire au développement cognitif, surtout chez les enfants." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de chutes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une faiblesse musculaire due à une carence en calbindine-2 augmente le risque de chutes." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de carence en calbindine-2 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé, une mauvaise alimentation et certaines maladies augmentent le risque." } }, { "@type": "Question", "name": "Les troubles métaboliques sont-ils un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles comme le diabète peuvent affecter les niveaux de calbindine-2." } }, { "@type": "Question", "name": "Le mode de vie sédentaire influence-t-il la calbindine-2 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire peut contribuer à une faiblesse musculaire et à des carences." } }, { "@type": "Question", "name": "Les régimes restrictifs sont-ils risqués ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les régimes restrictifs peuvent entraîner des carences en nutriments essentiels, y compris le calcium." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de troubles musculaires ou neurologiques peuvent augmenter le risque." } } ] } ] }

Sources (10000 au total)

Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.

Cognitive dysfunction is part of the broad spectrum of clinical manifestations in older untreated hereditary transthyretin amyloidosis patients with peripheral polyneuropathy.... The objective of this study is to systematically explore cognitive dysfunction in ATTRV30M amyloidosis patients whose disease course was modified by liver transplant (LT).... A series of 269 carriers of TTRVal30Met mutation treated with LT underwent a neuropsychological assessment. Clinical charts were reviewed to identify focal neurological episodes (FNEs), cognitive comp... Cognitive dysfunction was identified in 35 patients (13%)-14 (5%) had mild and 21 (8%) had moderate dysfunction. In comparison to normal cognition, both mild and moderate cognitive dysfunction patient... Consistent with the natural history of the disease, older age and higher severity of the disease are significantly associated and potentially predictors of cognitive dysfunction in ATTRV30M patients t...

Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.

The impact of cardiovascular diseases on cognition raises important research questions. The study aimed to investigate the relationship between demographic data, cardiovascular diseases, kidney diseas... A cross-sectional study of patients with cardiovascular diseases was performed. The Montreal Cognitive Assessment (MoCA) was applied for cognitive evaluation. Based on MoCA three groups were defined: ... Of 628 patients, 55.2% had mild CD, and the mean age was 67.95 (SD 9.53) years. Cα and Mω were 0.7, indicating good internal consistency. We found a moderate positive correlation between depression an... Mild CD was the most common in patients with cardiovascular diseases. Older age, lower education, being a non-smoker, and renal dysfunction were risk factors for both mild and advanced CD. Female gend...

Predictors of cognitive dysfunction one-year post COVID-19.

(a) To characterize the frequency of objective cognitive deficits and self-perceived cognitive difficulties and (b) to explore demographic and clinical predictors of cognitive dysfunction and cognitiv... One hundred and ten adults diagnosed with COVID-19 between March and November 2020, aged ≤ 74 years underwent a brief neuropsychological evaluation 12 months after infection, which included: Brief Vis... Twenty participants (18.2%) had cognitive dysfunction and 36 (33.3%) had cognitive complaints. Cognitive dysfunction was related to lower education, preinfection history of headache/migraine, and acut... A subset of individuals develops cognitive difficulties in the context of post-COVID syndrome. Results may support the protective effect of education, a known proxy of cognitive reserve. COVID-19 infe...

Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.

During the last years, a growing number of studies have investigated the link between cognitive dysfunction and rheumatoid arthritis (RA), highlighting the potential pathogenic role of several clinica... We performed a systematic review using PRISMA (Preferred Reported Items for Systematic Reviews and Meta-analysis) protocol. A systematic search was conducted in the PubMed/MEDLINE, EMBASE, LILACS, Sco... Five original studies were included, which provided data from 428 participants. Among plasma proteins, SHH was increased and TTR was reduced in patients with mild cognitive impairment; anti-myelin bas... Despite the relative scarcity of studies on this subject and the heterogeneity of results, we identified possible biomarkers for cognitive deficits in the RA population. Further longitudinal studies a...

Endothelial Dysfunction and Pre-Existing Cognitive Disorders in Stroke Patients.

The origin of pre-existing cognitive impairment in stroke patients remains controversial, with a vascular or a degenerative hypothesis.... To determine whether endothelial dysfunction is associated with pre-existing cognitive problems, lesion load and biological anomalies in stroke patients.... Patients originated from the prospective STROKDEM study. The baseline cognitive state, assessed using the IQ-CODE, and risk factors for stroke were recorded at inclusion. Patients with an IQ-CODE scor... A total of 86 patients were included (52 males; mean age 63.5 ± 11.5 years). Patients with abnormal RHI have hypertension or antihypertensive treatment more often. The baseline IQ-CODE was abnormal in... A vascular mechanism may be responsible for cognitive problems pre-existing stroke. The measurement of endothelial dysfunction after stroke could become an important element of follow-up, providing an...

Cognitive Dysfunction in Heart Failure: Pathophysiology and Implications for Patient Management.

There is increasing recognition of the prevalence and impact of cognitive dysfunction (CD) in heart failure (HF) patients. This contemporary review appraises the evidence for epidemiological associati... CD disproportionately affects heart failure patients, even accounting for known comorbid risk factors, and this may extend to subclinical left ventricular dysfunction. Neuroimaging studies now provide...

Frequency and risk factors for cognitive dysfunction in peritoneal dialysis patients.

There is limited data on cognition in patients undergoing peritoneal dialysis (PD). We assessed prevalence and associated risk factors of neurocognitive impairment (NCI) in PD patients.... A cross-sectional cohort study of 149 PD patients at a single centre between 2016 and 2020 who underwent neurocognitive screening at defined intervals by Addenbrooke's Cognitive Examination - Revised ... Patients on PD performed poorly in ACE-R screening compared to population norms, with discrepancy in all cognitive domains. In patients without CVD, attention and language domains were comparable to n... Patients on PD have higher prevalence of NCI than the general population, primarily with impairments in memory, fluency and visuospatial reasoning. CVD confers poorer performance in attention and lang...